Additionally, blood biomarkers, including Aβ, p‐tau, NfL, and GFAP, are measured to assess their utility in predicting dementia risk, as well as the predictive performance of the combination of blood biomarkers and cognitive function for diagnosing dementia. Here, MAPT is linked to dementia.